Research Using the NACC Database

Empirical Examination of Mismatched In-Vivo and Neuropathological Alzheimer's
Disease Diagnosis
 
   Lead Investigator:    Joesph Gaugler
   Institution      :    School of Nursing, University fo Minnesota
   E-Mail           :    gaug0015@umn.edu
   Proposal ID      :    221


   Publications:


1  Ascher-Svanum H, Gaugler J, Roth D, Fafowora T, Siderowf A, Beach T
   Characteristics of Patients Misdiagnosed with Alzheimer's Disease and Their Medication Use: An Analysis of the NACC-UDS Database
   Abstract  Alzheimers Dement,9:P734,2013,

   PUBLISHED



2  Gaugler JE, Ascher-Svanum H, Roth DL, Fafowora T, Siderowf A, Beach TG
   Characteristics of patients misdiagnosed with alzheimer's disease and their medication use: an analysis of the NACC-UDS database
   Journal Article  BMC Geriatrics,13:137,2013,PMC3878261

   PUBLISHED





   Proposal Description:
   Utilizing neuropathological verification and pre-mortem interview and clinical data from the National Alzheimer Coordination Center, the objective of this secondary analysis will be to examine cross-sectional and longitudinal variations between two cohorts of patients, matched on level of cognitive impairment, age, and gender: a) those who receive an in-vivo/pre-mortem diagnosis of Alzheimers disease and receive confirmed neuropathological diagnosis of Alzheimers disease (i.e., the matched group) and b) those who receive an in-vivo/pre-mortem diagnosis of Alzheimers disease but do not receive neuropathological confirmation of Alzheimers disease  (i.e., the mis-matched group).  We aim to examine statistical variations in patient sociodemographics, functional dependency, neuropsychiatric symptoms, depressive symptoms, medication use (e.g., anticholinesterate inhibitors, NMDA antagonists like Memantine and typical antipsychotics), and residential care use to determine the clinical ramifications of a mis-matched AD diagnosis. If samples sizes permit, we will also examine statistical variations among the aforementioned two groups with two additional cohorts: c) those who do not receive an in-vivo/pre-mortem diagnosis of Alzheimers disease but do receive confirmed neuropathological diagnosis of Alzheimers disease (i.e., mis-matched 2 group, and d) those who do not receive an in-vivo/pre-mortem diagnosis of Alzheimers disease and do not receive confirmed neuropathological diagnosis of Alzheimers disease (i.e., controls).